ipilimumab + Tyrosinase/gp100/MART-1 Peptides
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Intraocular Melanoma
Conditions
Intraocular Melanoma, Melanoma (Skin)
Trial Timeline
May 31, 2004 → Oct 31, 2009
NCT ID
NCT00084656About ipilimumab + Tyrosinase/gp100/MART-1 Peptides
ipilimumab + Tyrosinase/gp100/MART-1 Peptides is a phase 2 stage product being developed by Bristol Myers Squibb for Intraocular Melanoma. The current trial status is completed. This product is registered under clinical trial identifier NCT00084656. Target conditions include Intraocular Melanoma, Melanoma (Skin).
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00084656 | Phase 2 | Completed |
Competing Products
6 competing products in Intraocular Melanoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Mirabegron + Placebo | Astellas Pharma | Phase 1 | 33 |
| AZD4017 + Placebo + AZD4017 + Placebo | AstraZeneca | Phase 2 | 52 |
| OMS302 + Placebo | Omeros Corporation | Phase 3 | 72 |
| Part 1 OMS302 + Part 2 OMS302 + Part 2 Placebo | Omeros Corporation | Phase 3 | 72 |
| OMS302 + Placebo | Omeros Corporation | Phase 3 | 72 |
| cisplatin + sunitinib malate + tamoxifen citrate | Pacific Biosciences | Phase 2 | 44 |